Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556795 | 0.80 | CYP2D6 (0.37) | CYP2D6CYP2C19 | |
| SCHEMBL2460635 | 0.76 | CYP2D6 (0.52) | CYP2D6CYP2C19TSHR | |
| SCHEMBL3578430 | 0.75 | — | — | |
| SCHEMBL3391602 | 0.75 | — | — | |
| SCHEMBL2337647 | 0.74 | CYP2D6 (0.50) | CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL4745233 | 0.74 | CYP2D6 (0.50) | CYP2D6CYP2C19 | |
| SCHEMBL354239 | 0.74 | CYP2D6 (0.50) | CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL3899246 | 0.74 | CYP2D6 (0.50) | CYP2D6CYP2C19 | |
| SCHEMBL8200639 | 0.74 | — | — | |
| SCHEMBL15816508 | 0.74 | CYP2C19 (0.55) | CYP2D6CYP2C19ALDH1A1TSHRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565518-B2 | Hybrid cyclic libraries and screens thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-03-03 | — | — | US | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| CN-120136896-A | Disubstituted benzimidazole compound and application thereof | 暨南大学 | 2025-06-13 | — | — | CN | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240262867-A1 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-08-08 | — | — | US | disclosed |
| US-12049521-B2 | Hybrid cyclic libraries and screens thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2024-06-06 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2011124430-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-10-13 | — | — | WO | disclosed |
| US-20110166191-A1 | 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer | ZHANG SHIJUN | 2011-07-07 | — | — | US | disclosed |
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2254883-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| WO-2009121872-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009103552-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565518-B2 | Hybrid cyclic libraries and screens thereof | NOLC1, BCL6, CHP1 | CYP2D6 2295/4885CYP2C19 4882/4885ALDH1A1 4448/4885 |
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | CYP2D6 57/4885CYP2C19 81/4885ALDH1A1 886/4885 |
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | CYP2D6 1678/4885CYP2C19 408/4885ALDH1A1 81/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | CYP2D6 1678/4885CYP2C19 408/4885ALDH1A1 81/4885 |
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | CYP2D6 337/4885CYP2C19 504/4885ALDH1A1 1730/4885 |
| US-20100222324-A1 | Substituted Indole Compounds | BDKRB1, BDKRB2, EDNRB | CYP2D6 585/4885CYP2C19 783/4885ALDH1A1 1551/4885 |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | CYP2D6 3014/4885CYP2C19 2856/4885ALDH1A1 2660/4885 |
| US-20110166191-A1 | 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer | BRAF, MAP2K2, MAP2K1 | CYP2D6 3272/4885CYP2C19 4207/4885ALDH1A1 1791/4885 |
| US-12049521-B2 | Hybrid cyclic libraries and screens thereof | CACYBP, HSPBP1, PEBP1 | CYP2D6 4132/4885CYP2C19 4741/4885ALDH1A1 4588/4885 |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | CYP2D6 1678/4885CYP2C19 408/4885ALDH1A1 81/4885 |
| US-20240262867-A1 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF | CACYBP, HSPBP1, PEBP1 | CYP2D6 4132/4885CYP2C19 4741/4885ALDH1A1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.